Coalition of Cancer Cooperative Groups

Philadelphia, PA, United States

Coalition of Cancer Cooperative Groups

Philadelphia, PA, United States
SEARCH FILTERS
Time filter
Source Type

Jin M.,Statistics and Evaluation Center | Bauer J.,Statistics and Evaluation Center | Tis L.,Coalition of Cancer Cooperative Groups | Comis R.,Coalition of Cancer Cooperative Groups | And 2 more authors.
Journal of Cancer Education | Year: 2012

The American Cancer Society (ACS) and Coalition of Cancer Cooperative Groups (CCCG) provide a clinical trial (CT) information/matching/eligibility service (Clinical Trials Matching Service [CTMS]). Patients' demographic and clinical data, enrollment status, and selfreported barriers to CT participation were analyzed to assess enrollment rates and determinants of enrollment. During 3 years beginning October 1, 2007, the CTMS served 6,903 patients via the ACS call center. Among the 1,987 patients with follow-up information on enrollment, 219 (11.0%) enrolled in a CT; 48 of these 219 enrollees chose a CT they found via the CTMS. Patients were less likely to enroll if they had poor ECOG performance status (P0 0.032); were African American (P00.0003), were uninsured or had Medicaid coverage (P00.024), or had lower stage disease (P00.018). Enrollment varied by trial type/cancer site/system (P0.026). Several barriers significantly predicted nonenrollment. Broader availability of a CTMS might help improve patient participation in cancer clinical trials. © Springer Science+Business Media, LLC 2011.


Sparano J.A.,Yeshiva University | Pisano E.D.,University of North Carolina at Chapel Hill | White J.R.,Medical College of Wisconsin | Hunt K.K.,University of Houston | And 5 more authors.
Breast Cancer Research and Treatment | Year: 2010

Imaging and local therapy are important modalities for detection and management of localized breast cancer. Improvements in screening and local therapy have contributed to reduced breast cancer-associated morbidity and mortality. The Coalition of Cancer Cooperative Groups (CCCG) convened the Scientific Leadership Council (SLC) in breast cancer, an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for breast imaging and locoregional therapy, and also identified six trials judged to be of high priority. Current high priority trials included trials determining: (1) the role of accelerated partial breast versus whole-breast radiation (B39), (2) the feasibility, safety, and local and systemic control of small localized breast cancers treated with tumor ablation (Z 1072), (3) the role of removal of the primary cancer in selected patients with metastatic disease (E2108), and (4) the clinical and biological effects of pre-operative anti-HER2-directed and ER-directed therapies in localized or locally advanced breast cancer (B41, Z1031, Z1041). Ongoing and future trials will further refine optimal locoregional management, and additional research is required to develop improved screening methods and identify high risk populations most likely to benefit from targeted screening.


Baer A.R.,Research Policy Division | Baer A.R.,Hospital for Sick Children | Baer A.R.,Translational Research Management | Baer A.R.,Coalition of Cancer Cooperative Groups | And 12 more authors.
Journal of Oncology Practice | Year: 2011

When it comes to the conduct of clinical research, an investigator has numerous responsibilities. Because of the magnitude of this topic, we were unable to address all investigator responsibilities within the context of this article, but we hope the reader will access the external resources that were referenced for additional information. We also encourage the reader to pursue clinical investigator training to better understand the full totality of their responsibilities as an investigator. Copyright © 2011 by American Society of Clinical Oncology.


PubMed | Cleveland Clinic, Harvard University, Coalition of Cancer Cooperative Groups and Loyola University Chicago
Type: Journal Article | Journal: American journal of ophthalmology | Year: 2015

To characterize treatment patterns, overall survival (OS), and risk of second malignant tumors inpatients with retinoblastoma (RB) using the SEER (Surveillance Epidemiology and End Results) dataset.Cohort study.The SEER dataset was used to identify cases of RB using ICD-03 histology codes. Special permission was granted by the SEER administration to release chemotherapy information for this study (information that is not available in the publically available SEER dataset). Treatment of RB for patients with locoregional disease was characterized as surgical therapy, radiation therapy, chemotherapy, or any form thereof across 4 time periods from 1975 to 2010. Observed-to-expected (O/E) ratios for second malignant neoplasms were calculated with the use of age-specific incidence rates.There were 1452 cases of RB identified from 1975 to 2010, with 48% of patients being male and 30% presenting with bilateral disease. Treatment patterns over time of 1220 patients (84%) with localized disease showed an increase in chemotherapy ( any treatment) from 16.5% to 50.2% and a decrease in surgery ( any treatment) from 96.2% to 88.5% and decrease in radiation from 15.2% to 4.9% from the 1975-1979 time period to the 2000-2010 time period. The 10-year OS was 93.7%, 93.7%, 97.5%, and 97% for increasing time periods (1975-1979, 1980-1989, 1990-1999, 2000-2010, respectively; P= .029). Risk of second malignant neoplasms was highest among patients treated with radiotherapy with O/E ratio of 43 compared to 30 and 5 for chemotherapy and surgery alone, respectively.Treatment trends for RB show an increase in chemotherapy utilization with a decrease in radiation therapy from 1975 to 2010. Second malignant neoplasms occurred mainly in patients treated with radiation therapy. Our series demonstrates improvement in survival in contemporary time periods, which parallels a shift in therapy toward chemotherapy with a decline inradiation therapy.


Tamboli D.,Loyola University Chicago | Topham A.,Coalition of Cancer Cooperative Groups | Singh N.,Harvard University | Singh A.D.,Cleveland Clinic
American Journal of Ophthalmology | Year: 2015

Purpose To characterize treatment patterns, overall survival (OS), and risk of second malignant tumors in patients with retinoblastoma (RB) using the SEER (Surveillance Epidemiology and End Results) dataset. Design Cohort study. Methods The SEER dataset was used to identify cases of RB using ICD-03 histology codes. Special permission was granted by the SEER administration to release chemotherapy information for this study (information that is not available in the publically available SEER dataset). Treatment of RB for patients with locoregional disease was characterized as surgical therapy, radiation therapy, chemotherapy, or any form thereof across 4 time periods from 1975 to 2010. Observed-to-expected (O/E) ratios for second malignant neoplasms were calculated with the use of age-specific incidence rates. Results There were 1452 cases of RB identified from 1975 to 2010, with 48% of patients being male and 30% presenting with bilateral disease. Treatment patterns over time of 1220 patients (84%) with localized disease showed an increase in chemotherapy (± any treatment) from 16.5% to 50.2% and a decrease in surgery (± any treatment) from 96.2% to 88.5% and decrease in radiation from 15.2% to 4.9% from the 1975-1979 time period to the 2000-2010 time period. The 10-year OS was 93.7%, 93.7%, 97.5%, and 97% for increasing time periods (1975-1979, 1980-1989, 1990-1999, 2000-2010, respectively; P =.029). Risk of second malignant neoplasms was highest among patients treated with radiotherapy with O/E ratio of 43 compared to 30 and 5 for chemotherapy and surgery alone, respectively. Conclusion Treatment trends for RB show an increase in chemotherapy utilization with a decrease in radiation therapy from 1975 to 2010. Second malignant neoplasms occurred mainly in patients treated with radiation therapy. Our series demonstrates improvement in survival in contemporary time periods, which parallels a shift in therapy toward chemotherapy with a decline in radiation therapy. © 2015 by Elsevier Inc. All Rights Reserved.


PubMed | Coalition of Cancer Cooperative Groups
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016

6581 Background: Adult enrollment in cancer clinical trials is 3-5%, even though two thirds of cancer patients are receptive to enrolling in a study. Closing this gap requires convenient delivery of comprehensive information on relevant trials and nearby sites to patients.The American Cancer Society (ACS) and the Coalition of Cancer Cooperative Groups (Coalition) joined forces to provide information from TrialCheck, the Coalitions caBIG bronze level certified cancer clinical trial database and matching/eligibility tool via the ACS 24-7-365 national call center (800-ACS-2345) and website ( www.Cancer.org ). Trial search parameters included demographic, clinical and geographic information. The ACS conducts person-to-person interaction and follow up with the individuals to assess enrollment status and barriers to trial participation.In the first four months of operation the service provided 5,183 TrialCheck screenings for 2,557 individuals, leading to 727 fulfillment orders. The top 5 cancers screened were breast (661 screenings), lung (397), bone/soft tissue (338), prostate (337) and head & neck (246); 203 screenings for cancer prevention/control trials were also conducted. The fulfillment orders yielded 7,198 protocol matches, with an average number of 9.9 matches of interest (based on orders of trial protocol and site location information) in the state where the patient resides. 25.8% of matches of interest were for phase I trials, 8.1% for phase I/II, 42.0% for phase II, 8.4% for phase II/III and 15.7% for phase III.Of those patients and caregivers who conducted a clinical trials search, 28.4% completed the process through to requesting the trial matches be sent to them for them to consider participation and discuss with their physician. The impact of this service on clinical trial enrollment will be monitored as data mature. No significant financial relationships to disclose.

Loading Coalition of Cancer Cooperative Groups collaborators
Loading Coalition of Cancer Cooperative Groups collaborators